Table 1 Inclusion and exclusion criteria

Inclusion criteria

diagnosis of NSCLC (adenocarcinoma or LC-anaplastic carcinoma)

tumour stage IIIb (wet) or IV

wild-type epidermal growth factor receptor (EGFR)

first-line therapy with pemetrexed/platin or vinorelbine/platin

MT with pemetrexed (in the case of remission or stable disease) or, alternatively, with erlotinib (only in the case of stable disease)

aged between 18 and 90 years

written informed consent

Exclusion criteria

obvious cognitive impairment